Alnylam Near 52-Week Low With Amvuttra in Focus
Alnylam Pharmaceuticals fell 2.16% to $295.47 Monday, hovering near its 52-week low despite broader market gains. The company named Benjamin F. Cravatt to its board, expanding to 11 directors. First-quarter revenue hit $1.04 billion, driven by Amvuttra sales. Options activity showed high implied volatility for July $210 calls.